LifeStance Health Group, Inc.

LifeStance Health Group, Inc. operates an outpatient mental-health platform through subsidiaries and supported practices. Psychiatrists, nurses, psychologists and therapists provide in-person and virtual care, with insurance reimbursement a major source of revenue. Common shares trade as LFST on the Nasdaq Global Select Market.

Quarterly record

Clinician headcount grew 11% to 8,863, while visits increased 17%. Hiring, acquired practices and higher productivity contributed. Management attributed higher revenue per visit primarily to improved insurance reimbursement rates.

Center Margin deducts direct center costs from revenue but excludes corporate overhead and depreciation and amortization.

Adjusted EBITDA excludes interest, taxes, depreciation, amortization, stock compensation, contingent-consideration remeasurement, asset disposals, transaction and executive-transition costs, selected litigation and strategic-initiative costs, real estate restructuring and cloud-software implementation amortization.

Quarterly stock-based compensation was $18.2 million, compared with $18.3 million a year earlier. LifeStance also excluded $1.7 million of strategic-initiative expense associated with its electronic health records system from adjusted EBITDA. Reported operating income includes those operating expenses.

Earlier expectations and new outlook

Management's August Q3 forecast was revenue of $420 million to $440 million and adjusted EBITDA of $49 million to $59 million. Actual results exceeded both upper limits.

The Q4 outlook is revenue of $446 million to $466 million and adjusted EBITDA of $56 million to $64 million. Revenue growth, clinician capacity and the pace of spending on technology and support functions remain the main operating measures to follow.

Cash generation, buybacks and financing

Nine-month operating cash flow was $170.0 million, versus $88.6 million a year earlier. Cash property and equipment spending was $37.4 million, versus $25.2 million, leaving $132.6 million and $63.4 million respectively. Better earnings, prepaid-asset movements and accrued expenses contributed to the cash improvement.

Cash at September 30 was $218.8 million, down from $225.9 million in June and $248.6 million at the prior year-end. Nine-month uses included $122.4 million of share repurchases, $24.9 million of employee share-settlement taxes, $10.9 million of principal repayments and $9.6 million of acquisitions net of cash acquired.

The August $100 million buyback authorization replaced the earlier $100 million program. Actual Q3 repurchases used $24.8 million; approximately $75.4 million of authority remained in September. The September secondary offering sold existing holders' shares and generated no proceeds for LifeStance.

Term-loan principal was $271.9 million at September 30, maturing in December 2029. The reported $255.5 million net long-term debt figure deducts the current portion and financing costs, rather than cash. The $100 million revolving facility was undrawn. Operating lease liabilities were a separate $205.5 million.

Acquisitions and financial controls

LifeStance completed four practice acquisitions during the first nine months for $14.1 million of consideration: $10.1 million cash and $4.0 million of acquisition-date contingent consideration. The contingent liability subsequently rose to $6.4 million after remeasurement.

Financial-reporting control weaknesses originally identified in connection with the 2019 statements remained unremediated at September 30. Management reported further improvements to accounting and IT controls, with sustained operation and testing still required before remediation can be confirmed.